AFF1
AFF1 (ALF transcription elongation factor 1, also known as AF4, AF-4, FEL, PBM1 and MLLT2) is a nuclear member of the AF4/FMR2 family. It regulates RNA polymerase II-mediated transcription through elongation and chromatin remodelling functions. Browse Assay Genie's current range of AFF1 research reagents below, or read on for the biology behind the target.
AFF1 plays an essential role in activating transcription elongation from RNA polymerase II promoters after transcriptional pausing in response to DNA damage. During this response, AFF1-mediated transcriptional recovery requires poly-ADP-ribosylation of AFF1 by PARP1. More broadly, the protein acts as a regulator of RNA polymerase II-mediated transcription through elongation and chromatin remodelling functions. HGNC places it in both the AF4/FMR2 family and the super elongation complex gene group.
The AFF1 gene encodes a member of the AF4/lymphoid nuclear protein related to the Fragile X E syndrome (FRAXE) family, which has been implicated in human childhood lymphoblastic leukaemia, fragile chromosome X intellectual disability and ataxia. Family members share three conserved domains: an N-terminal homology domain, an AF4/lymphoid nuclear protein domain and a C-terminal homology domain. UniProt annotates the protein as nuclear, and alternative splicing produces multiple transcript variants. The mouse ortholog is Aff1.
AFF1 is the prevalent mixed-lineage leukaemia (MLL) fusion gene associated with spontaneous acute lymphoblastic leukaemia, which explains several of its earlier names, including myeloid/lymphoid or mixed-lineage leukaemia translocated to 2 (MLLT2) and pre-B-cell monocytic leukaemia partner 1 (PBM1). RNA interference screens have shown that the gene promotes expression of CD133, a plasma membrane glycoprotein required for leukaemia cell survival.
AFF1 regulates RNA polymerase II-mediated transcription through elongation and chromatin remodelling, making it a focus for studies of transcriptional control.
AFF1 drives transcriptional recovery after damage-induced pausing, a process that requires its poly-ADP-ribosylation by PARP1.
AFF1 is the prevalent MLL fusion partner in spontaneous acute lymphoblastic leukaemia and supports expression of CD133, needed for leukaemia cell survival.
As an AF4/FMR2 family member grouped with the super elongation complex, AFF1 is relevant to studies of elongation machinery.
AFF1 is a nuclear regulator of RNA polymerase II transcription, acting through elongation and chromatin remodelling. It is essential for restarting elongation from Pol II promoters after DNA damage-induced pausing, and this recovery requires poly-ADP-ribosylation of AFF1 by PARP1.
The approved name is ALF transcription elongation factor 1; UniProt uses AF4/FMR2 family member 1. Aliases and previous symbols include AF-4, AF4, FEL, PBM1 and MLLT2, the last reflecting its identification as a mixed-lineage leukaemia translocation partner. Alternative splicing gives multiple transcript variants.
Yes. AFF1 is the prevalent MLL fusion gene in spontaneous acute lymphoblastic leukaemia, and the AF4/FMR2 family has been implicated in childhood lymphoblastic leukaemia, fragile X intellectual disability and ataxia. AFF1 also promotes CD133 expression. A mouse ortholog, Aff1, exists; check the datasheet of any product for its validated reactivity.
Other AF4/FMR2 family members, super elongation complex components, DNA damage response proteins and leukaemia-associated markers.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P51825; product specifications from Assay Genie datasheets.